Health

Covid-19 Vaccine Development sees Unparalleled Progress

At least seven teams are developing vaccines using the Sars-CoV-2 virus in a weakened or inactivated form, such as those against measles and polio. Sinovac Biotech in Beijing is testing an inactivated form of Sars-CoV-2 in humans.

Hindustan Times, New Delhi

Coronavirus India Cases Live Updates: Coronavirus cases in India have crossed 56,000-mark and death toll due to COVID 19 is nearing 1900-mark. In India, there are 37,729 coronavirus active cases and so far 16,790 COVID-19 positive patients have been cured or discharged. A total of 1890 people died due to the highly contagious virus and one has been migrated, as per details shared by the Union Health and Family Welfare Ministry. In the last 24 hours India has recorded 3,390 coronavirus positive cases and 103 COVID-19 related deaths.

While the lockdown is on across India with several relaxations, flouting of social distancing norms has become a cause of concern. The whole world is endeavoring to find the Coronavirus vaccine. Efforts were also on in labs across India to manufacture the COVID 19 vaccine to check the deadly virus.

US President Donald Trump’s re-election campaign took off with him telling potential voters that a coronavirus vaccine will be ready by the end of 2020, even as European leaders pledged to raise the US $8.3 billion to “kickstart an unprecedented global co-operation” between scientists, industry, governments, and philanthropies for vaccine development.

Global efforts to develop a vaccine against the coronavirus disease (Covid-19) have progressed at an unprecedented pace aiming to stop the spread of the pandemic, which has infected over 3.9 million people, killed 270,740, and wrecked global economies within four months.

Small bottles labelled with a “Vaccine COVID-19” sticker and a medical syringe.

Pune-based Serum Institute of India started work 10 days ago on manufacturing in parallel to the human safety trials, the Oxford experimental vaccine, ChAdOx1 nCoV-19, at its own risk. “SII plans to begin manufacturing the ChAdOx1 vaccine in anticipation of the clinical trials in the UK succeeding by September/October. SII will initiate the manufacture at its own risk to jump-start manufacturing and have enough doses available, if the clinical trials work,” said SII CEO, Adar Poonawalla in a statement.

WHO last week organised a meeting of vaccine manufacturers and national regulatory authorities in its South-East Asia Region, of which India, Indonesia and Thailand are a part. The three countries are among the world’s largest vaccine manufacturers.

“The manufacturing capacity that exists in the region is of the quality and scale required to produce and roll out a Covid-19 vaccine globally. This region is a vaccine manufacturing powerhouse, and it must now also play a lead role in overcoming the ongoing pandemic,” said Dr. Poonam Khetrapal Singh, regional director, WHO South-East Asia. At the virtual meeting, leading manufacturers from India, Indonesia, and Thailand discussed timelines and production capacity, while regulatory bodies discussed how to fast-track processes to make large scale production and deployment of Covid-19 vaccines possible by the end of the year.

Tags
Show More

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also

Close
Back to top button
Close

Adblock Detected

Please consider supporting us by disabling your ad blocker